Research Reveals Pancreatic Cancer's Immunotherapy Block

Study also identifies potential path to making immunotherapy effective against the deadly, treatment-resistant cancer

Apr. 11, 2026 at 1:28am

Got story updates? Submit your updates here. ›

An ethereal, ghostly X-ray image showing the complex internal structures of a pancreatic tumor, with intricate networks of glowing lines representing the dynamic interactions between cancer cells and immune cells.Cutting-edge research reveals how pancreatic tumors manipulate the immune system, providing new hope for immunotherapy breakthroughs.San Diego Today

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer — and identified a promising strategy to overcome that resistance. The study, published in the journal Immunity, shows that pancreatic tumors actively reshape their immune environment by co-opting regulatory immune cells that normally shut down tumor-killing cells. By reprogramming those cells, the research reveals a potential pathway to make immunotherapy effective against one of the deadliest and most treatment-resistant cancers.

Why it matters

Pancreatic cancer is one of the deadliest and most treatment-resistant forms of cancer, with immunotherapy largely failing to provide benefits for patients. This research provides critical insights into why pancreatic tumors are able to evade the immune system's cancer-fighting capabilities, and identifies a potential new approach to making immunotherapy effective against this devastating disease.

The details

The study found that pancreatic tumors contain large numbers of regulatory T cells, or Tregs, which normally shut down tumor-killing immune cells. By reprogramming these Tregs, the researchers were able to convert them from immune suppressors into cells that support anti-tumor activity. This suggests that treatments may need to both turn on the immune system and overcome the tumor's ability to shut it down in order to make immunotherapy viable for pancreatic cancer patients.

  • The study was published in the journal Immunity on April 11, 2026.

The players

Katelyn Byrne

The senior author of the study, an assistant professor of cell, developmental and cancer biology in the OHSU School of Medicine and a member of the OHSU Brenden-Colson Center for Pancreatic Care.

OHSU

The Oregon Health & Science University, where the research was conducted.

Immunity

The scientific journal in which the study was published.

Got photos? Submit your photos here. ›

What they’re saying

“Pancreatic cancer is incredibly resistant to most therapies. Even when we know the immune system is capable of long-lasting protection, it's been very difficult to get that response to work in this disease.”

— Katelyn Byrne, Assistant Professor, OHSU School of Medicine

“Tregs are very suppressive immune cells. If there are a lot of them in a tumor, it's extremely hard to get an anti-tumor immune response going.”

— Katelyn Byrne, Assistant Professor, OHSU School of Medicine

“We didn't expect this. The therapy doesn't directly target Tregs, but as a secondary effect of turning on the immune response, those Tregs changed their behavior. Cells that were shutting down the immune reaction suddenly started supporting tumor killing.”

— Katelyn Byrne, Assistant Professor, OHSU School of Medicine

What’s next

Clinical trials in humans using the combination therapy approach should be underway within a few years. Byrne's lab is now working to further map the complex communication between immune cells inside pancreatic tumors and to determine whether the reprogrammed cells provide long-term immune protection.

The takeaway

This research provides critical insights into why pancreatic tumors are able to evade the immune system's cancer-fighting capabilities, and identifies a potential new approach to making immunotherapy effective against this devastating disease. By reprogramming the regulatory T cells that normally suppress the immune response, the researchers were able to convert them into cells that support anti-tumor activity, opening up new possibilities for combination therapies that could finally make immunotherapy a viable option for pancreatic cancer patients.